141 related articles for article (PubMed ID: 35328198)
1. PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples.
Ronchi A; Zito Marino F; Moscarella E; Brancaccio G; Argenziano G; Troiani T; Napolitano S; Franco R; Cozzolino I
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328198
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples.
Ronchi A; Zito Marino F; Toni G; Pagliuca F; Russo D; Signoriello G; Moscarella E; Brancaccio G; Argenziano G; Franco R; Cozzolino I
J Clin Pathol; 2022 Jan; 75(1):45-49. PubMed ID: 33509946
[TBL] [Abstract][Full Text] [Related]
3. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
4. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
[TBL] [Abstract][Full Text] [Related]
5. Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall.
Van Winden VI; Wong DD; Wood BA; Filion P; Harvey NT
Pathology; 2024 Feb; 56(1):47-51. PubMed ID: 37989630
[TBL] [Abstract][Full Text] [Related]
6. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience.
Carvajal P; Zoroquiain P
Pathol Res Pract; 2023 Oct; 250():154776. PubMed ID: 37696245
[TBL] [Abstract][Full Text] [Related]
7. Utility of Sry-Related HMG-Box Gene 10 (SOX10) as a marker of melanoma in effusion cytology.
Dermawan JKT; Underwood D; Policarpio-Nicolas ML
Diagn Cytopathol; 2019 Jul; 47(7):653-658. PubMed ID: 30794352
[TBL] [Abstract][Full Text] [Related]
8. PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma.
Glutsch V; Wobser M; Schilling B; Gesierich A; Goebeler M; Kneitz H
Dermatopathology (Basel); 2022 May; 9(2):148-157. PubMed ID: 35645230
[TBL] [Abstract][Full Text] [Related]
9. Sarcomatoid Dedifferentiated Melanoma: The Diagnostic Role of Next-Generation Sequencing.
Valiga AA; Fuller CG; Doyle JA; Lee JB
Am J Dermatopathol; 2022 Apr; 44(4):282-286. PubMed ID: 34726188
[TBL] [Abstract][Full Text] [Related]
10. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
Ruby KN; Li Z; Yan S
J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
[TBL] [Abstract][Full Text] [Related]
12. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of PRAME immunohistochemistry in PEComa family of tumors and morphologic mimics with emphasis on the gynecologic tract.
Smithgall MC; Liu-Jarin X; Chen X; Singh K; Quddus MR; Cimic A
Hum Pathol; 2023 Aug; 138():12-17. PubMed ID: 37209921
[TBL] [Abstract][Full Text] [Related]
14. PReferentially Expressed Antigen in MElanoma (PRAME): preliminary communication on a translational tool able to early detect Oral Malignant Melanoma (OMM).
Cascardi E; Cazzato G; Ingravallo G; Dellino M; Lupo C; Casatta N; Ballini A; Pacifici A; Marenzi G; Sammartino G; Maiorano E; Tatullo M
J Cancer; 2023; 14(4):628-633. PubMed ID: 37057287
[TBL] [Abstract][Full Text] [Related]
15. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
16. PRAME expression in 155 cases of metastatic melanoma.
Gradecki SE; Slingluff CL; Gru AA
J Cutan Pathol; 2021 Apr; 48(4):479-485. PubMed ID: 32939793
[TBL] [Abstract][Full Text] [Related]
17. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna.
Gradecki SE; Valdes-Rodriguez R; Wick MR; Gru AA
Histopathology; 2021 Jun; 78(7):1000-1008. PubMed ID: 33280156
[TBL] [Abstract][Full Text] [Related]
18. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
[TBL] [Abstract][Full Text] [Related]
20. Metastatic triple-negative breast carcinoma mimicking melanoma: A potential diagnostic pitfall.
Fliorent R; Benedetto C; Theroux Z
J Cutan Pathol; 2024 May; ():. PubMed ID: 38767140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
